These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38321212)

  • 21. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
    Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma.
    Yang H; Zhao Y; Song W; Fan G
    Int J Biol Macromol; 2024 Jan; 254(Pt 1):127627. PubMed ID: 37884243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the Mechanism of
    Zhu J; Han M; Yang Y; Feng R; Hu Y; Wang Y
    Comb Chem High Throughput Screen; 2024; 27(1):157-167. PubMed ID: 37366364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 14-3-3ζ and aPKC-ι synergistically facilitate epithelial-mesenchymal transition of cholangiocarcinoma via GSK-3β/Snail signaling pathway.
    Yang Y; Liu Y; He JC; Wang JM; Schemmer P; Ma CQ; Qian YW; Yao W; Zhang J; Qi WP; Fu Y; Feng W; Yang T
    Oncotarget; 2016 Aug; 7(34):55191-55210. PubMed ID: 27409422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elucidation of the anti-colorectal cancer mechanism of
    Wang G; Guo C; Pi H; Wang Y; Lin S; Bi K; Zhang M; Wang N; Zhao G
    Aging (Albany NY); 2024 Aug; 16(16):12008-12028. PubMed ID: 39177661
    [No Abstract]   [Full Text] [Related]  

  • 27. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Adiponectin Receptor Agonist Inhibits Cholangiocarcinoma via Adenosine Monophosphate-activated Protein Kinase.
    Bui KC; Nguyen TML; Barat S; Scholta T; Xing J; Bhuria V; Sipos B; Wilkens L; Nguyen LT; Le HS; Velavan TP; Bozko P; Plentz RR
    Curr Med Chem; 2024; 31(28):4534-4548. PubMed ID: 38361349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor.
    Obchoei S; Detarya M; Boonnate P; Saranaruk P; Vaeteewoottacharn K; Mahalapbutr P; Okada S; Wongkham S
    Asian Pac J Cancer Prev; 2022 Oct; 23(10):3379-3386. PubMed ID: 36308362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway.
    Pei YF; Liu J; Cheng J; Wu WD; Liu XQ
    Am J Pathol; 2019 Aug; 189(8):1637-1653. PubMed ID: 31345467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
    Liu B; Hu Y; Qin L; Peng XB; Huang YX
    Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated plasma pharmacochemistry and network pharmacology to explore the mechanism of Gerberae Piloselloidis Herba in treatment of allergic asthma.
    Zhou K; Lu D; You J; Liu T; Sun J; Lu Y; Pan J; Li Y; Liu C
    J Ethnopharmacol; 2022 Nov; 298():115624. PubMed ID: 35970314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway.
    Zang MD; Hu L; Fan ZY; Wang HX; Zhu ZL; Cao S; Wu XY; Li JF; Su LP; Li C; Zhu ZG; Yan M; Liu BY
    J Transl Med; 2017 Feb; 15(1):52. PubMed ID: 28241766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Emodin in the Treatment of Bladder Cancer Based on Network Pharmacology and Experimental Verification.
    Liu F; Li J; Zhou B; Shen Y; Tang J; Han J; Chen C; Shao K; Chen H; Yuan L
    Comb Chem High Throughput Screen; 2024; 27(11):1661-1675. PubMed ID: 38504574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Mechanism of Caulis Spatholobi in the Treatment of Chronic Myeloid Leukemia based on Network Pharmacology and Experimental Verification.
    Wu Y; Lian F; Chen H; Zhang C; Wei L; Tian H
    Curr Comput Aided Drug Des; 2024; 20(1):49-59. PubMed ID: 37073142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of the effect and mechanism of Scutellaria barbata D. Don in the treatment of ovarian cancer based on network pharmacology and in vitro experimental verification.
    Zhang J; Qi C; Li H; Ding C; Wang L; Wu H; Dai W; Wang C
    Medicine (Baltimore); 2023 Dec; 102(51):e36656. PubMed ID: 38134066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apigenin inhibits proliferation and differentiation of cardiac fibroblasts through AKT/GSK3β signaling pathway.
    Kan H; Wang P; Yang Y; Jia H; Liu A; Wang M; Ouyang C; Yang X
    J Ethnopharmacol; 2024 Nov; 334():118518. PubMed ID: 38964628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.
    Lu S; Sun X; Zhou Z; Tang H; Xiao R; Lv Q; Wang B; Qu J; Yu J; Sun F; Deng Z; Tian Y; Li C; Yang Z; Yang P; Rao B
    Front Immunol; 2023; 14():1235575. PubMed ID: 37799727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective Effects and Mechanisms of Luteolin against Acute Respiratory Distress Syndrome: Network Pharmacology and
    Li Q; Chen J; Ren Y; Yang Z; Wang M; Zhang W; Cao L; Sun H; Nie S; Sun Z
    Curr Pharm Des; 2024; 30(18):1404-1418. PubMed ID: 38616753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating network pharmacology, molecular docking and experimental verification to explore the therapeutic effect and potential mechanism of nomilin against triple-negative breast cancer.
    Wu Z; Xiang H; Wang X; Zhang R; Guo Y; Qu L; Zhou J; Xiao Y
    Mol Med; 2024 Sep; 30(1):166. PubMed ID: 39342122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.